J0218 HCPCS Level II Code: Injection, olipudase alfa-rpcp, 1 mg

Drug products (NDC)

CMS ASP NDC-HCPCS Crosswalk · 2026 Q3

Medicare Part B payment limit (ASP + 6%): $404.95

58468-0050-01 — Xenpozyme — Genzyme Corporation (size 1 × qty 1 (1 MG per billing unit))

58468-0051-01 — Xenpozyme — Genzyme Corporation (size 1 × qty 1 (1 MG per billing unit))

From the CMS ASP NDC-HCPCS Crosswalk and Part B Payment Limit File. Payment limits apply per HCPCS billing code, not per package.

Contextual Map

Every relationship of J0218 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.

Nearest codes (36)

• J0200 — Injection, alatrofloxacin mesylate, 100 mg[Sibling]— CMS HCPCS Level II code set
• J0202 — Injection, alemtuzumab, 1 mg[Sibling]— CMS HCPCS Level II code set
• J0205 — Injection, alglucerase, per 10 units[Sibling]— CMS HCPCS Level II code set
• J0206 — Injection, allopurinol sodium, 1 mg[Sibling]— CMS HCPCS Level II code set
• J0207 — Injection, amifostine, 500 mg[Sibling]— CMS HCPCS Level II code set
• J0208 — Injection, sodium thiosulfate (pedmark), 100 mg[Sibling]— CMS HCPCS Level II code set
• J0209 — Injection, sodium thiosulfate (hope), 100 mg[Sibling]— CMS HCPCS Level II code set
• J0210 — Injection, methyldopate hcl, up to 250 mg[Sibling]— CMS HCPCS Level II code set
• and 28 more

Change history

• April 1, 2023 — Added to the code set [Change history]— CMS release files (code change ledger)

Sources for this page

Codes, titles, notes, index terms and mappings on this page are transcribed from the datasets below. Relationships MedCoder computed and text MedCoder wrote are labelled where they appear.

Code, descriptors, coverage and pricing attributes Official source data

CMS HCPCS Alpha-Numeric (ANWEB) release — July 2026 quarterly update Release, file and checksum · Publisher’s page

Drug products Official source data

CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q3 (July 2026 release); FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24 Release, file and checksum · Publisher’s page

Change history and date-of-service validity Official source data

CMS HCPCS quarterly update files, ingested into the change ledger Release, file and checksum · Publisher’s page

Comparisons, relationships and the contextual map MedCoder structured relationship

Computed by MedCoder from the tabular notes and tables above; every derived relationship is marked as derived where it appears

Summary and FAQ answers MedCoder explanation

Written by MedCoder to explain the sources above: drafted with AI assistance, checked by a person against the release files, and labelled as MedCoder text where it appears. Not official text.

Labels on this page: Official source data · MedCoder structured relationship · MedCoder explanation. How to read the labels · All data sources and release dates

Nearest Codes in This Family

Official HCPCS Level II classifications closest to J0218 in its code family, with their registry titles.

• J0210 — Injection, methyldopate hcl, up to 250 mg
• J0211 — Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg (nithiodote)
• J0215 — Injection, alefacept, 0.5 mg
• J0216 — Injection, alfentanil hydrochloride, 500 micrograms
• J0217 — Injection, velmanase alfa-tycv, 1 mg
• J0219 — Injection, avalglucosidase alfa-ngpt, 4 mg
• J0220 — Injection, alglucosidase alfa, 10 mg, not otherwise specified
• J0221 — Injection, alglucosidase alfa, (lumizyme), 10 mg
• J0222 — Injection, patisiran, 0.1 mg
• J0223 — Injection, givosiran, 0.5 mg